Publication: Candesartan Cilexetil In Vitro–In Vivo Correlation: Predictive Dissolution as a Development Tool
Loading...
Author
Figueroa-Campos, Andrés Ignacio
Sánchez-Dengra, Bárbara
Merino, Virginia
Dahan, Arik
Gonzalez-Alvarez, Isabel
García Arieta, Alfredo
Gonzalez-Alvarez, Marta
Bermejo, Marival
Journal Title
Journal ISSN
Volume Title
Date
Citation
Pharmaceutics 2020, 12(7), 633;
Conference
Publisher
MDPI
Abstract
The main objective of this investigation was to develop an in vitro–in vivo correlation
(IVIVC) for immediate release candesartan cilexetil formulations by designing an in vitro dissolution
test to be used as development tool. The IVIVC could be used to reduce failures in future bioequivalence
studies. Data from two bioequivalence studies were scaled and combined to obtain the dataset for the
IVIVC. Two-step and one-step approaches were used to develop the IVIVC. Experimental solubility
and permeability data confirmed candesartan cilexetil. Biopharmaceutic Classification System (BCS)
class II candesartan average plasma profiles were deconvoluted by the Loo-Riegelman method to
obtain the oral fractions absorbed. Fractions dissolved were obtained in several conditions in USP
II and IV apparatus and the results were compared calculating the f2 similarity factor. Levy plot
was constructed to estimate the time scaling factor and to make both processes, dissolution and
absorption, superimposable. The in vitro dissolution experiment that reflected more accurately the
in vivo behavior of the products of candesartan cilexetil employed the USP IV apparatus and a
three-step pH buffer change, from 1.2 to 4.5 and 6.8, with 0.2% of Tween 20. This new model was
able to predict the in vivo differences in dissolution and it could be used as a risk-analysis tool for
formulation selection in future bioequivalence trials.
